New Delhi: Prime Minister Narendra Modi will embark on a three city visit today to personally review the COVID-19 vaccine development and manufacturing process. Prime Minister’s Office in a tweet said that Mr Modi will visit the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute of India in Pune.
It said, as India enters a decisive phase of the fight against COVID-19, Prime Minister Narendra Modi’s visit to these facilities and discussions with the scientists will help him get a first hand perspective of the preparations, challenges and roadmap in India’s endeavour to vaccinate its citizens.
Prime Minister Narendra Modi will first visit the Zydus Cadila Pharmaceutical’s vaccine development facility at Zydus Biotech Park near Ahmedabad today morning to personally review the Covid vaccine development process.
AIR Ahmedabad correspondent reports that the Zydus plant which is working on ZyCoV-D, a Covid19 vaccine candidate is located in Changodar area of Ahmedabad Gujarat. A helipad facility has been set up close to the plant for the Prime Minister’s visit.
Later, the Prime Minister is expected to fly to Pune, to visit the Serum Institute to review the production of corona vaccine COVISHIELD. Our Pune Correspondent reports that Mr. Modi will discuss with the concerned officials about the overall supply and distribution system after the successful testing of this vaccine.
According to the schedule, after arrival at Lohegaon airport, the Prime Minister will be flown directly to Serum Institute by a special helicopter and will be at the institute for about an hour. The Prime Minister will then leave for Hyderabad from Lohegaon Airport. AIR correspondent reports, the Prime Minister is scheduled to arrive at Hakimapet Air Force Station, Hyderabad this afternoon.
Mr. Modi is expected to reach the vaccine manufacturing facility of Bharat Biotech International Limited (BBIL) and review the Covid-19 Vaccine manufacturing process. The BBIL is engaged in the manufacturing of COVID-19 vaccine called Covaxin in collaboration with the Indian Council of Medical Research (ICMR).
